Group 3 Pulmonary Hypertension: From Bench to Bedside. Issue 9 (29th April 2022)

• Record Type: Journal Article
• Authors: Singh, Navneet; Dorfmüller, Peter; Shlobin, Oksana A.; Ventetuolo, Corey E.
• Is Part Of: Circulation research. Volume 130:Issue 9(2022)
• Page Start: 1404
• Page End: 1422
• Publication Date: 2022-04-29
• Subjects: hypertension, pulmonary -- hypoxia -- lung diseases, interstitial -- prevalence -- ventricular dysfunction, right; Cardiovascular system -- Periodicals; Blood -- Circulation -- Periodicals; Blood Circulation; Cardiovascular System; Vascular Diseases; Sang -- Circulation -- Périodiques; Appareil cardiovasculaire -- Périodiques; 612.1
• DOI: 10.1161/CIRCRESAHA.121.319970
• Languages: English
• ISSNs: 0009-7330

Abstract

Abstract : Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3 PH in the most recent classification system. Prevalence of these diseases is increasing over time, creating a growing need for effective therapeutic options. Recent approval of the first pulmonary arterial hypertension therapy for the treatment of Group 3 PH related to interstitial lung disease represents an encouraging advancement. This review focuses on molecular mechanisms contributing to pulmonary vasculopathy in chronic hypoxia, the pathology and epidemiology of Group 3 PH, the right ventricular dysfunction observed in this population and clinical trial data that inform the use of pulmonary vasodilators in Group 3 PH.